Cryptyx is developing novel antibiotics and antivirals to combat infectious disease by tackling CDC and NIAID priority agents. Of the dozens of novel cryptic metabolites discovered using our platform technology thus far, five leads have been identified with excellent in vitro and in vivo properties, with biological activities that surpass those of extant cures.

Our Programs

To prevent and treat life-threatening infections